<br>        Inclusion Criteria:<br><br>          -  Type of subject: Outpatient<br><br>          -  Informed Consent: A signed and dated written informed consent prior to study<br>             participation<br><br>          -  Age: 40 years of age or older at Visit 1.<br><br>          -  Gender: Male and female subjects are eligible to participate in the study. Female<br>             subjects are eligible to participate if not pregnant (as confirmed by a negative urine<br>             human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the<br>             following conditions applies:<br><br>        Non-reproductive potential defined as:<br><br>        Pre-menopausal females with one of the following: Documented tubal ligation Documented<br>        hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal<br>        occlusion Hysterectomy Documented Bilateral Oophorectomy Postmenopausal defined as 12<br>        months of spontaneous amenorrhea. Females on hormone replacement therapy (HRT) and whose<br>        menopausal status is in doubt will be required to use one of the highly effective<br>        contraception methods if they wish to continue their HRT during the study. Otherwise, they<br>        must discontinue HRT to allow confirmation of postmenopausal status prior to study<br>        enrolment.<br><br>        Reproductive potential and agrees to follow one of the options listed below 30 days prior<br>        to the first dose of study medication and until at least five terminal half-lives OR until<br>        any continuing pharmacologic effect has ended, whichever is longer after the last dose of<br>        study medication and completion of the follow-up visit. This list does not apply to females<br>        of reproductive potential with same sex partners, when this is their preferred and usual<br>        lifestyle or for subjects who are and will continue to be abstinent from penile-vaginal<br>        intercourse on a long term and persistent basis.<br><br>        Contraceptive subdermal implant that meets <1 percent (%) rate of failure per year, as<br>        stated in the product label Intrauterine device or intrauterine system that meets <1% rate<br>        of failure per year, as stated in the product label Oral Contraceptive, either combined or<br>        progestogen alone Injectable progestogen Contraceptive vaginal ring Percutaneous<br>        contraceptive patches Male partner sterilization with documentation of azoospermia prior to<br>        the female subjects entry into the study, and this male is the sole partner for that<br>        subject These allowed methods of contraception are only effective when used consistently,<br>        correctly and in accordance with the product label. The investigator is responsible for<br>        ensuring that subjects understand how to properly use these methods of contraception.<br><br>          -  Diagnosis: An established clinical history of COPD in accordance with the definition<br>             by the American Thoracic Society/European Respiratory Society as follows: Chronic<br>             obstructive pulmonary disease is a preventable and treatable disease state<br>             characterized by airflow limitation that is not fully reversible. The airflow<br>             limitation is usually progressive and is associated with an abnormal inflammatory<br>             response of the lungs to noxious particles or gases, primarily caused by cigarette<br>             smoking.<br><br>          -  Smoking History: Current or former cigarette smokers with a history of cigarette<br>             smoking of >=10 pack-years. Former smokers are defined as those who have stopped<br>             smoking for at least 6 months prior to Visit 1. Number of pack years = (number of<br>             cigarettes per day / 20) x number of years smoked (e.g. 20 cigarettes per day for 10<br>             years, or 10 cigarettes per day for 20 years both equal 10 pack-years). Note: pipe and<br>             cigar cannot be used to calculate pack-year history.<br><br>          -  Severity of Disease: A post-albuterol/salbutamol FEV1/FVC ratio of <=0.70 and a<br>             post-albuterol/salbutamol FEV1 >=30 and <=70% of predicted normal at Visit 1.<br><br>        Note: Percent predicted will be calculated using the European Respiratory Society Global<br>        Lung Function Initiative reference equations.<br><br>        Exclusion Criteria:<br><br>          -  Asthma: Subjects with a current diagnosis of asthma. (subjects with a prior history of<br>             asthma are eligible if they have a current diagnosis of COPD).<br><br>          -  Other Respiratory Disorders: Known respiratory disorders other than COPD including but<br>             not limited to alpha-1 antitrypsin deficiency, active tuberculosis, bronchiectasis,<br>             sarcoidosis, lung fibrosis, pulmonary hypertension unrelated to COPD, and interstitial<br>             lung disease. Allergic rhinitis is not exclusionary.<br><br>          -  Other Diseases/Abnormalities: Any significant diseases (including uncontrolled<br>             hypertension, diabetes and thyroid disease) that in the opinion of the investigator or<br>             the study medical monitor would put the safety of the subject at risk through study<br>             participation, or which would affect study analyses if the diseases/condition<br>             exacerbated during the study.<br><br>          -  Hepatitis: Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C<br>             antibody test result at screening Visit 1 or within 3 months prior to first dose of<br>             study treatment. (subjects with positive hepatitis C antibody due to prior resolved<br>             disease can be enrolled only if a confirmatory negative Hepatitis C ribonucleic acid<br>             (RNA) polymerase chain reaction (PCR) test is obtained).<br><br>          -  Liver Disease: Current or chronic history of liver disease, known hepatic or biliary<br>             abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).<br><br>          -  Cancer: A current malignancy or previous history of cancer in remission for <5 years<br>             prior to Visit 1 (localised basal cell or squamous cell carcinoma of the skin that has<br>             been resected is not exclusionary.) Any current or previous history of throat cancer.<br><br>          -  Chest X-Ray: A chest X-ray or computed tomography (CT) scan that reveals evidence of<br>             clinically significant abnormalities not believed to be due to the presence of COPD. A<br>             chest X-ray must be taken at Visit 1 if a chest X-ray or CT scan is not available<br>             within 6 months prior to Visit 1. For subjects in Germany, if a chest X-ray (or CT<br>             scan) is not available in the 6 months prior to Visit 1 the subject will not be<br>             eligible for the study.<br><br>          -  Drug Allergy: A history of hypersensitivity or allergy to any beta adrenergic<br>             receptor-agonist, sympathomimetic, anticholinergic/anti-muscarinic receptor<br>             antagonist, or lactose/milk protein, which in the opinion of the investigator or<br>             GlaxoSmithKline (GSK) medical monitor contraindicates study participation.<br><br>          -  Diseases Preventing Use of Anticholinergic: Medical diagnosis of narrow- angle<br>             glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the<br>             study investigator would prevent use of an inhaled anticholinergic.<br><br>          -  Poorly controlled COPD: defined as the occurrence of 'acute worsening of COPD that is<br>             managed with corticosteroid and/or antibiotics or t